Novel kidney injury biomarkers.
New biomarkers are currently under development for acute kidney injury and chronic kidney disease. Panels of validated biomarkers are most likely to be required to obtain information that will help in delineating acute versus chronic disease, the pathogenetic nature of the process, the severity, and the capacity for reversibility. Glycoprotein non-metastatic melanoma protein-b, a protein associated with regulation of inflammation and autophagy, is in an intermediate stage of development as a kidney injury biomarker.
Adler
Sharon
S
Division of Nephrology and Hypertension, Harbor-UCLA Medical Center, Torrance, California 90509, USA. sadler@LABiomed.org
D000419:Albuminuria; D000818:Animals; D015415:Biomarkers / Q000032:analysis* / Q000097:blood / Q000652:urine; D003404:Creatinine / Q000097:blood; D005919:Glomerular Filtration Rate; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000175:diagnosis* / Q000652:urine; D008562:Membrane Glycoproteins / Q000652:urine; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D015415:Biomarkers; C503042:GPNMB protein, human; D008562:Membrane Glycoproteins; D003404:Creatinine